Gain detailed insights into the trading activity of Congress members for Editas Medicine on our government trades page. Stay updated on how elected officials are investing in EDIT.

Editas Medicine - Government Trades

Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Medicine,Development,Laboratory:,Caucasian,Female,Scientist,Using,Microscope,,Analyzes,Petri

Analyst Color

Biotech

News

Downgrades

Health Care

Analyst Ratings

General

EDIT

Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of-concept timelines.

JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution

Walmart’s 8 Top Holiday Deals To Snag Right Now

Price Target

Markets

Trading Ideas

AVGO

CIEN

Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday

TOL, Toll Brothers

NDSN

This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Movers

Editas Medicine pivots to in vivo gene editing, extends cash runway to Q2 2027, and reduces its workforce by 65%. The company reports breakthroughs in HSC and liver editing.

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Analyst sees stock go up

Equities

BEAM

CRSP

Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13.

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Earnings

Earnings Misses

Penny Stocks

Small Cap

AKRO

ANVS

VRTX

Editas Medicine, Inc. (NASDAQ: EDIT) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a loss of 56 cents per share in the year-ago quarter.

Editas Q2 Earnings &amp; Revenues Miss Estimates, Stock Down

Dati deludenti sull'occupazione USA e i mercati crollano

Pre-Market Outlook

BMBL

BOOT

CENTA

LYFT

PETQ

Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday

Intraday Update

ACMR

ADIL

ALHC

ANTE

APLT

BAND

BETS

BIDU

BYND

CONNEXA SPORTS TECH INC by Connexa Sports Technologies Inc.

CNXA

CNXC

COCO

CRGE

EBAY

FLYW

GTLS

IFBD

IMNN

INGN

IXHL

KITT

LAZR

LFST

LMND

MSTR

MVLA

NRDY

NVAX

OCEA

OGEN

PAYO

PGNY

PSNY

QRTEA

RBOT

RVLV

RXRX

SMXT

TGTX

URBN

VANI

VIPS

VTNR

VTVT

VTYX

Shares of  Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday.

Advance Auto Parts Reports Q4 Results, Joins B&amp;G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday

ALLO

AMCX

ATGL

AVDX

BHIL

BILL

BOOM

BSFC

CVRX

CYTO

DMTK

DOCN

DRIO

DRMA

EIGR

ENGN

ENLV

EXPE

FIGS

FNKO

FOXF

FTNT

HIPO

HOWL

INSG

LILM

MCRB

MERC

NEXI

NLOP

NVOS

OTLY

PBLA

PCTY

PRLB

PUYI

RDFN

SYRA

TNON

TRUP

UDMY

VIVK

VSME

Gainers


	Benson Hill, Inc. (NYSE: BHIL) shares jumped 48.1% to $0.3740.


Why Fortinet Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Editas Medicine Inc

Press Releases

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Government Trades

Editas Medicine Inc

top performing EDIT trades

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga